# Per Soelberg SÃ¸rensen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3744973/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 337<br>papers | 34,965<br>citations | 7551<br>77<br>h-index | 4101<br>175<br>g-index |
| 347<br>all docs | 347<br>docs citations | 347<br>times ranked | 27936<br>citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder. Pattern Recognition, 2022, 123, 108403. | 5.1 | 26 |
| 2 | The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456. | 1.4 | 16 |
| 3 | Population Pharmacokineticâ€“BÂCell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis. CNS Drugs, 2022, 36, 283-300. | 2.7 | 15 |
| 4 | Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis. CNS Drugs, 2022, 36, 569-589. | 2.7 | 6 |
| 5 | Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 188-197. | 1.4 | 8 |
| 6 | Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 556-562. | 0.9 | 7 |
| 7 | Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. Frontiers in Neurology, 2021, 12, 647811. | 1.1 | 17 |
| 8 | Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Multiple Sclerosis Journal, 2021, 27, 1543-1555. | 1.4 | 33 |
| 9 | Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS. Multiple Sclerosis and Related Disorders, 2021, 50, 102813. | 0.9 | 7 |
| 10 | Transcriptome and Function of Novel Immunosuppressive Autoreactive Invariant Natural Killer T Cells That Are Absent in Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1065. | 3.1 | 1 |
| 11 | The effectiveness of natalizumab vs fingolimodâ€“A comparison of international registry studies. Multiple Sclerosis and Related Disorders, 2021, 53, 103012. | 0.9 | 8 |
| 12 | Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, . | 3.1 | 15 |
| 13 | Relapses add to permanent disability in relapsing multiple sclerosis patients. Multiple Sclerosis and Related Disorders, 2021, 53, 103029. | 0.9 | 5 |
| 14 | Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project. Multiple Sclerosis and Related Disorders, 2021, 54, 103107. | 0.9 | 3 |
| 15 | Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. Lancet Neurology, The, 2021, 20, 917-929. | 4.9 | 42 |
| 16 | Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110582. | 1.5 | 9 |
| 17 | Predictors of treatment outcome in patients with paediatric onset multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 964-975. | 1.4 | 11 |
| 18 | Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon-Î². Multiple Sclerosis and Related Disorders, 2020, 39, 101894. | 0.9 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis. Multiple Sclerosis and Related Disorders, 2020, 37, 101431. | 0.9 | 6 |
| 20 | Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 67-74. | 0.9 | 15 |
| 21 | The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain, 2020, 143, 2637-2652. | 3.7 | 56 |
| 22 | Comorbidity in Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 851. | 1.1 | 89 |
| 23 | The window of opportunity for treatment of progressive multiple sclerosis. Current Opinion in Neurology, 2020, 33, 262-270. | 1.8 | 27 |
| 24 | Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063. | 1.4 | 21 |
| 25 | Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044. | 1.4 | 39 |
| 26 | Expert opinion on the use of cladribine tablets in clinical practice. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642093501. | 1.5 | 23 |
| 27 | Initial high-efficacy disease-modifying therapy in multiple sclerosis. Neurology, 2020, 95, e1041-e1051. | 1.5 | 83 |
| 28 | Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurological Sciences, 2020, 41, 1647-1650. | 0.9 | 48 |
| 29 | Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study. Multiple Sclerosis and Related Disorders, 2020, 40, 101956. | 0.9 | 18 |
| 30 | Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. CNS Drugs, 2020, 34, 269-280. | 2.7 | 49 |
| 31 | Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsingâ€“Remitting Multiple Sclerosis Patients? A Narrative Review. Neurology and Therapy, 2020, 9, 55-66. | 1.4 | 18 |
| 32 | Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19. Journal of Medical Internet Research, 2020, 22, e19992. | 2.1 | 155 |
| 33 | Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1298-1305. | 1.4 | 24 |
| 34 | Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1444-1451. | 1.4 | 47 |
| 35 | Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science, 2019, 365, . | 6.0 | 710 |
| 36 | Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 29, 168-174. | 0.9 | 94 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. Lancet Neurology, The, 2019, 18, 185-197. | 4.9 | 110 |
| 38 | MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. Trials, 2019, 20, 263. | 0.7 | 58 |
| 39 | Worsening of disability caused by relapses in multiple sclerosis: A different approach. Multiple Sclerosis and Related Disorders, 2019, 32, 1-8. | 0.9 | 28 |
| 40 | Comparative effectiveness of teriflunomide and dimethyl fumarate. Neurology, 2019, 92, e1811-e1820. | 1.5 | 36 |
| 41 | Pulsed immune reconstitution therapy in multiple sclerosis. Therapeutic Advances in Neurological Disorders, 2019, 12, 175628641983691. | 1.5 | 54 |
| 42 | The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis. Current Opinion in Neurology, 2019, 32, 320-326. | 1.8 | 60 |
| 43 | Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27. | 1.1 | 22 |
| 44 | The Multiple Sclerosis Care Unit. Multiple Sclerosis Journal, 2019, 25, 627-636. | 1.4 | 90 |
| 45 | Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. Journal of Neurology, 2019, 266, 306-315. | 1.8 | 18 |
| 46 | Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Multiple Sclerosis Journal, 2019, 25, 819-827. | 1.4 | 46 |
| 47 | Progressive multiple sclerosis, cognitive function, and quality of life. Brain and Behavior, 2018, 8, e00875. | 1.0 | 48 |
| 48 | Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsingâ€“remitting multiple sclerosis: the CLARITY Extension study. Therapeutic Advances in Neurological Disorders, 2018, 11, 175628561775336. | 1.5 | 45 |
| 49 | ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 96-120. | 1.4 | 458 |
| 50 | Disability in progressive MS is associated with T2 lesion changes. Multiple Sclerosis and Related Disorders, 2018, 20, 73-77. | 0.9 | 6 |
| 51 | Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173. | 4.9 | 4,605 |
| 52 | Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. Multiple Sclerosis Journal, 2018, 24, 590-603. | 1.4 | 101 |
| 53 | Safety and efficacy of cladribine tablets in patients with relapsingâ€“remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Multiple Sclerosis Journal, 2018, 24, 1594-1604. | 1.4 | 227 |
| 54 | Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. Cell, 2018, 175, 1679-1687.e7. | 13.5 | 115 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | 039â€...Rates of lymphopenia in years 1â€“4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, A16.2-A16. | 0.9 | 3 |
| 56 | Early safety and efficacy of fingolimod treatment in Denmark. Acta Neurologica Scandinavica, 2017, 135, 129-133. | 1.0 | 15 |
| 57 | A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Multiple Sclerosis Journal, 2017, 23, 234-241. | 1.4 | 38 |
| 58 | Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis. Acta Neurologica Scandinavica, 2017, 136, 330-337. | 1.0 | 8 |
| 59 | Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships. European Journal of Neurology, 2017, 24, 825-834. | 1.7 | 21 |
| 60 | Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents. CNS Drugs, 2017, 31, 357-371. | 2.7 | 11 |
| 61 | Defining active progressive multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1727-1735. | 1.4 | 34 |
| 62 | Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. Neurology, 2017, 89, 1668-1675. | 1.5 | 57 |
| 63 | Employment, disability pension and income for children with parental multiple sclerosis. Multiple Sclerosis Journal, 2017, 23, 1148-1156. | 1.4 | 9 |
| 64 | High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Multiple Sclerosis Journal, 2017, 23, 675-685. | 1.4 | 38 |
| 65 | Safety concerns and risk management of multiple sclerosis therapies. Acta Neurologica Scandinavica, 2017, 136, 168-186. | 1.0 | 65 |
| 66 | Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet, The, 2017, 389, 1347-1356. | 6.3 | 252 |
| 67 | Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796. | 3.7 | 139 |
| 68 | Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS ONE, 2017, 12, e0170395. | 1.1 | 34 |
| 69 | Laquinimod Safety Profile. International Journal of MS Care, 2017, 19, 16-24. | 0.4 | 15 |
| 70 | The Danish Multiple Sclerosis Treatment Register. Clinical Epidemiology, 2016, Volume 8, 549-552. | 1.5 | 35 |
| 71 | Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. PLoS ONE, 2016, 11, e0162752. | 1.1 | 41 |
| 72 | Minocycline added to subcutaneous interferon Î²â€‘1a in multiple sclerosis: randomized <scp>RECYCLINE</scp> study. European Journal of Neurology, 2016, 23, 861-870. | 1.7 | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. Multiple Sclerosis Journal, 2016, 22, 1386-1396. | 1.4 | 118 |
| 74 | Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. Multiple Sclerosis Journal, 2016, 22, 944-954. | 1.4 | 21 |
| 75 | Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study. Journal of Neurology, 2016, 263, 2229-2237. | 1.8 | 10 |
| 76 | Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark. Journal of Neurology, 2016, 263, 2484-2493. | 1.8 | 40 |
| 77 | Haematopoietic stem cell transplants should be a second-line therapy for highly active MS â€“ NO. Multiple Sclerosis Journal, 2016, 22, 1260-1263. | 1.4 | 4 |
| 78 | Neurofilament in CSFâ€”A biomarker of disease activity and long-term prognosis in multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1112-1113. | 1.4 | 15 |
| 79 | Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. Multiple Sclerosis and Related Disorders, 2016, 10, 169-173. | 0.9 | 68 |
| 80 | Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort. Multiple Sclerosis and Related Disorders, 2016, 10, 181-186. | 0.9 | 16 |
| 81 | NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. Neuron, 2016, 92, 333-335. | 3.8 | 24 |
| 82 | Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 912-914. | 0.9 | 8 |
| 83 | Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. Journal of Immunological Methods, 2016, 430, 1-9. | 0.6 | 18 |
| 84 | Generic glatiramer acetate â€” a step toward cheaper MS drugs?. Nature Reviews Neurology, 2016, 12, 5-6. | 4.9 | 6 |
| 85 | Ozanimod: a better or just another S1P receptor modulator?. Lancet Neurology, The, 2016, 15, 345-347. | 4.9 | 11 |
| 86 | Cytokine profiles show heterogeneity of interferon-Î² response in multiple sclerosis patients. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e202. | 3.1 | 34 |
| 87 | The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Therapeutic Advances in Neurological Disorders, 2016, 9, 44-52. | 1.5 | 103 |
| 88 | Association between age at onset of multiple sclerosis and vitamin D levelâ€“related factors. Neurology, 2016, 86, 88-93. | 1.5 | 28 |
| 89 | Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 926-934. | 1.4 | 23 |
| 90 | Endogenous Interferon-Î²-Inducible Gene Expression and Interferon-Î²-Treatment Are Associated with Reduced T Cell Responses to Myelin Basic Protein in Multiple Sclerosis. PLoS ONE, 2015, 10, e0118830. | 1.1 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1414-1422. | 1.4 | 18 |
| 92 | A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. Multiple Sclerosis Journal, 2015, 21, 263-281. | 1.4 | 273 |
| 93 | The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 305-317. | 1.4 | 381 |
| 94 | Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 1557-1565. | 1.4 | 17 |
| 95 | Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. Multiple Sclerosis Journal, 2015, 21, 1723-1729. | 1.4 | 56 |
| 96 | Therapeutic interference with leukocyte recirculation in multiple sclerosis. European Journal of Neurology, 2015, 22, 434-442. | 1.7 | 9 |
| 97 | Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. Nature Genetics, 2015, 47, 717-726. | 9.4 | 310 |
| 98 | The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. Multiple Sclerosis Journal, 2015, 21, 332-341. | 1.4 | 39 |
| 99 | A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 282-293. | 1.4 | 131 |
| 100 | A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 294-304. | 1.4 | 79 |
| 101 | A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 342-349. | 1.4 | 100 |
| 102 | A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 318-331. | 1.4 | 131 |
| 103 | Secondary Progressive and Relapsing Remitting Multiple Sclerosis Leads to Motor-Related Decreased Anatomical Connectivity. PLoS ONE, 2014, 9, e95540. | 1.1 | 17 |
| 104 | Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. Multiple Sclerosis Journal, 2014, 20, 577-587. | 1.4 | 40 |
| 105 | CorticalN-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis. Neurological Research, 2014, 36, 701-708. | 0.6 | 9 |
| 106 | Prediction of response to interferon therapy in multiple sclerosis. Acta Neurologica Scandinavica, 2014, 130, 268-275. | 1.0 | 21 |
| 107 | The chemokine receptorCCR5 Î”32allele in natalizumab-treated multiple sclerosis. Acta Neurologica Scandinavica, 2014, 129, 27-31. | 1.0 | 9 |
| 108 | Gender effects on treatment response to interferon-beta in multiple sclerosis. Acta Neurologica Scandinavica, 2014, 130, 374-379. | 1.0 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | New management algorithms in multiple sclerosis. Current Opinion in Neurology, 2014, 27, 246-259. | 1.8 | 95 |
| 110 | Gender and autoimmune comorbidity in multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 1244-1251. | 1.4 | 28 |
| 111 | Effects of fingolimod in relapsing-remitting multiple sclerosis. Lancet Neurology, The, 2014, 13, 526-527. | 4.9 | 7 |
| 112 | FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nature Medicine, 2014, 20, 272-282. | 15.2 | 141 |
| 113 | A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. Journal of Neurology, 2014, 261, 773-783. | 1.8 | 168 |
| 114 | Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. Journal of Neurology, 2014, 261, 1170-1177. | 1.8 | 127 |
| 115 | Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis. Journal of Neuroimmunology, 2014, 276, 195-201. | 1.1 | 8 |
| 116 | Gene expression in smoking and non-smoking patients with multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 49. | 1.1 | 1 |
| 117 | Physical and social environment and the risk of multiple sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 600-606. | 0.9 | 21 |
| 118 | Defining the clinical course of multiple sclerosis. Neurology, 2014, 83, 278-286. | 1.5 | 2,344 |
| 119 | Multiple sclerosis impairs regional functional connectivity in the cerebellum. NeuroImage: Clinical, 2014, 4, 130-138. | 1.4 | 42 |
| 120 | Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 179-187. | 1.4 | 27 |
| 121 | MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. Journal of Neurology, 2013, 260, 1136-1146. | 1.8 | 46 |
| 122 | Differential microRNA expression in blood in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1849-1857. | 1.4 | 110 |
| 123 | Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics, 2013, 45, 1353-1360. | 9.4 | 1,213 |
| 124 | Gene expression analysis of relapsingâ€“remitting, primary progressive and secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1841-1848. | 1.4 | 29 |
| 125 | Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study). Multiple Sclerosis and Related Disorders, 2013, 2, 141-146. | 0.9 | 6 |
| 126 | Resting-state connectivity of pre-motor cortex reflects disability in multiple sclerosis. Acta Neurologica Scandinavica, 2013, 128, n/a-n/a. | 1.0 | 33 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 559-566. | 1.4 | 39 |
| 128 | Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab. Multiple Sclerosis Journal, 2013, 19, 1226-1229. | 1.4 | 18 |
| 129 | Reproduction and the risk of multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 1604-1609. | 1.4 | 54 |
| 130 | Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. Multiple Sclerosis Journal, 2013, 19, 1533-1538. | 1.4 | 92 |
| 131 | CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. Multiple Sclerosis Journal, 2013, 19, 877-884. | 1.4 | 75 |
| 132 | Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis. Expert Review of Neurotherapeutics, 2013, 13, 1309-1317. | 1.4 | 5 |
| 133 | Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression. PLoS ONE, 2013, 8, e57820. | 1.1 | 213 |
| 134 | Multiple Sclerosis Management â€“ A Changing Landscape 2013. European Neurological Review, 2013, 8, 105. | 0.5 | 0 |
| 135 | Prediction of antibody persistency from antibody titres to natalizumab. Multiple Sclerosis Journal, 2012, 18, 1493-1499. | 1.4 | 21 |
| 136 | Effects of neutralizing antibodies to interferon beta in multiple sclerosis: a logical paradox. Multiple Sclerosis Journal, 2012, 18, 131-132. | 1.4 | 6 |
| 137 | Deaths and disability from natalizumab are no longer tolerable: No â€“ (they can be avoided). Multiple Sclerosis Journal, 2012, 18, 1070-1072. | 1.4 | 2 |
| 138 | Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 305-313. | 1.4 | 21 |
| 139 | Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study. Neurological Research, 2012, 34, 52-58. | 0.6 | 11 |
| 140 | FOXP3, CBLBandITCHgene expression and cytotoxic T lymphocyte antigen 4 expression on CD4+CD25high T cells in multiple sclerosis. Clinical and Experimental Immunology, 2012, 170, 149-155. | 1.1 | 34 |
| 141 | Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. Neuroscience Letters, 2012, 530, 155-160. | 1.0 | 17 |
| 142 | Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Multiple Sclerosis Journal, 2012, 18, 143-152. | 1.4 | 220 |
| 143 | Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. Journal of Neuroinflammation, 2012, 9, 215. | 3.1 | 66 |
| 144 | Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis. Clinical Drug Investigation, 2012, 32, 15-27. | 1.1 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Endogenous and Recombinant Type I Interferons and Disease Activity in Multiple Sclerosis. PLoS ONE, 2012, 7, e35927. | 1.1 | 14 |
| 146 | Effect of Natalizumab on Circulating CD4+ T-Cells in Multiple Sclerosis. PLoS ONE, 2012, 7, e47578. | 1.1 | 59 |
| 147 | Cognitive deficits in multiple sclerosis: correlations with T2 changes in normal appearing brain tissue. Acta Neurologica Scandinavica, 2012, 125, 338-344. | 1.0 | 18 |
| 148 | Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis. Acta Neurologica Scandinavica, 2012, 126, 421-427. | 1.0 | 34 |
| 149 | Cladribine tablets for relapsingâ€“remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. Multiple Sclerosis and Related Disorders, 2012, 1, 49-54. | 0.9 | 29 |
| 150 | Correlation between antiâ€interferonâ€Î²2 binding and neutralizing antibodies in interferonâ€Î²2â€treated multiple sclerosis patients. European Journal of Neurology, 2012, 19, 1311-1317. | 1.7 | 15 |
| 151 | Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 2011, 476, 214-219. | 13.7 | 2,400 |
| 152 | Why does the northâ€“south gradient of incidence of multiple sclerosis seem to have disappeared on the Northern hemisphere?. Journal of the Neurological Sciences, 2011, 311, 58-63. | 0.3 | 63 |
| 153 | Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. Journal of the Neurological Sciences, 2011, 311, S29-S34. | 0.3 | 15 |
| 154 | Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 | 1.4 | 109 |
| 155 | Cladribine in the treatment of multiple sclerosis. Clinical Investigation, 2011, 1, 317-326. | 0.0 | 3 |
| 156 | Disease protection and interleukinâ€10 induction by endogenous interferonâ€Î²2 in multiple sclerosis?. European Journal of Neurology, 2011, 18, 266-272. | 1.7 | 40 |
| 157 | Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. European Journal of Human Genetics, 2011, 19, 1100-1103. | 1.4 | 9 |
| 158 | Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurology, The, 2011, 10, 329-337. | 4.9 | 199 |
| 159 | Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. Lancet Neurology, The, 2011, 10, 691-701. | 4.9 | 114 |
| 160 | Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurology, The, 2011, 10, 745-758. | 4.9 | 247 |
| 161 | Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Multiple Sclerosis Journal, 2011, 17, 1074-1078. | 1.4 | 50 |
| 162 | Neutralizing antibodies against interferon-Î²2 do not predispose antibodies against natalizumab. Neurology, 2011, 76, 759-760. | 1.5 | 14 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. Multiple Sclerosis Journal, 2011, 17, 32-42. | 1.4 | 64 |
| 164 | Principles of a new treatment algorithm in multiple sclerosis. Expert Review of Neurotherapeutics, 2011, 11, 351-362. | 1.4 | 23 |
| 165 | The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurology, The, 2010, 9, 520-532. | 4.9 | 914 |
| 166 | Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurology, The, 2010, 9, 740-750. | 4.9 | 188 |
| 167 | Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. Lancet Neurology, The, 2010, 9, 672-680. | 4.9 | 70 |
| 168 | EFNS guidelines on diagnosis and management of neuromyelitis optica. European Journal of Neurology, 2010, 17, 1019-1032. | 1.7 | 376 |
| 169 | Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis. Genes and Immunity, 2010, 11, 142-154. | 2.2 | 23 |
| 170 | Demyelination versus remyelination in progressive multiple sclerosis. Brain, 2010, 133, 2983-2998. | 3.7 | 261 |
| 171 | A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010, 362, 416-426. | 13.9 | 791 |
| 172 | Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. Multiple Sclerosis Journal, 2010, 16, 942-949. | 1.4 | 29 |
| 173 | Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 431-436. | 1.4 | 88 |
| 174 | Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 323-328. | 1.4 | 21 |
| 175 | The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2009, 15, 601-605. | 1.4 | 23 |
| 176 | The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain, 2009, 132, 1175-1189. | 3.7 | 1,182 |
| 177 | Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. Journal of Neuroimmunology, 2009, 212, 125-131. | 1.1 | 65 |
| 178 | Comparison of clinical neurological function and CT response during chemotherapy for initial brain metastases from small cell lung cancer. Acta Neurologica Scandinavica, 2009, 89, 372-377. | 1.0 | 2 |
| 179 | NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurology, The, 2009, 8, 519-529. | 4.9 | 95 |
| 180 | Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP. Immunology, 2009, 128, e451-61. | 2.0 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Management of patients with neutralizing antibodies against interferonâ€beta: stop IFNâ€beta therapy or wait for the antibodies to go away?. European Journal of Neurology, 2009, 16, 1-2. | 1.7 | 7 |
| 182 | Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferonâ€Î². European Journal of Neurology, 2009, 16, 43-47. | 1.7 | 25 |
| 183 | Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. European Journal of Neurology, 2009, 16, 420-423. | 1.7 | 84 |
| 184 | How effective is natalizumab as secondâ€line treatment for multiple sclerosis in daily clinical praxis?. European Journal of Neurology, 2009, 16, 287-288. | 1.7 | 1 |
| 185 | Identification of new sensitive biomarkers for the in vivo response to interferonâ€Î² treatment in multiple sclerosis using DNAâ€array evaluation. European Journal of Neurology, 2009, 16, 1291-1298. | 1.7 | 50 |
| 186 | Safety and immunogenicity of a new formulation of interferon Î²-1a (RebifÂ® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Multiple Sclerosis Journal, 2009, 15, 219-228. | 1.4 | 67 |
| 187 | The SH2D2A Gene -Contributions to Our Future Understanding of Multiple Sclerosis. European Neurological Review, 2009, 4, 68. | 0.5 | 0 |
| 188 | Editorial. Journal of Neurology, 2008, 255, 1-2. | 1.8 | 0 |
| 189 | EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. European Journal of Neurology, 2008, 15, 893-908. | 1.7 | 272 |
| 190 | The effect of Î²-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. Clinical Immunology, 2008, 129, 80-89. | 1.4 | 14 |
| 191 | REGARD: what can we learn from randomised, open-label, head-to-head studies?. Lancet Neurology, The, 2008, 7, 864-866. | 4.9 | 4 |
| 192 | The SH2D2A gene and susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2008, 197, 152-158. | 1.1 | 14 |
| 193 | Intravenous Polyclonal Human Immunoglobulins in Multiple Sclerosis. Neurodegenerative Diseases, 2008, 5, 8-15. | 0.8 | 15 |
| 194 | 447: Remyelination is extensive in a subset of multiple sclerosis patients. Journal of Clinical Neuroscience, 2008, 15, 358. | 0.8 | 0 |
| 195 | Oral fumarate for relapsing-remitting multiple sclerosis. Lancet, The, 2008, 372, 1447-1448. | 6.3 | 7 |
| 196 | Gene expression analysis of interferon-Î² treatment in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 615-621. | 1.4 | 35 |
| 197 | Review: Neutralizing antibodies against interferon-beta. Therapeutic Advances in Neurological Disorders, 2008, 1, 125-141. | 1.5 | 33 |
| 198 | Can we spot the IFNÂ nonresponders?. Neurology, 2008, 71, 1936-1937. | 1.5 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Is the treatment effect of IFN-Î² restored after the disappearance of neutralizing antibodies?. Multiple Sclerosis Journal, 2008, 14, 837-842. | 1.4 | 23 |
| 200 | Fatal neurogenic pulmonary edema in a patient with progressive multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 711-715. | 1.4 | 19 |
| 201 | Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-Î² treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. Multiple Sclerosis Journal, 2008, 14, 622-630. | 1.4 | 64 |
| 202 | Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. Journal of International Medical Research, 2008, 36, 204-8; author reply 208-10. | 0.4 | 3 |
| 203 | Health-related quality of life in secondary progressive multiple sclerosis. Multiple Sclerosis Journal, 2007, 13, 386-392. | 1.4 | 46 |
| 204 | Multiple Sclerosis After Infectious Mononucleosis. Archives of Neurology, 2007, 64, 72. | 4.9 | 170 |
| 205 | Are ex vivo neutralising antibodies against IFN-Î² always detrimental to therapeutic efficacy in multiple sclerosis?. Multiple Sclerosis Journal, 2007, 13, 616-621. | 1.4 | 38 |
| 206 | Neutralizing antibodies to interferon beta: Assessment of their clinical and radiographic impact: An evidence report: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology, 2007, 69, 1552-1553. | 1.5 | 11 |
| 207 | Immunogenicity and tolerability of an investigational formulation of interferon-Î²1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clinical Therapeutics, 2007, 29, 1128-1145. | 1.1 | 38 |
| 208 | A follow-up study of Nordic multiple sclerosis candidate gene regions. Multiple Sclerosis Journal, 2007, 13, 584-589. | 1.4 | 0 |
| 209 | The gap between effect of drugs and effectiveness of treatments. Journal of the Neurological Sciences, 2007, 259, 128-132. | 0.3 | 4 |
| 210 | Widespread Demyelination in the Cerebellar Cortex in Multiple Sclerosis. Brain Pathology, 2007, 17, 38-44. | 2.1 | 301 |
| 211 | Using measurements of neutralizing antibodies: the challenge of IFNâ€Î² therapy. European Journal of Neurology, 2007, 14, 850-859. | 1.7 | 43 |
| 212 | Resource allocation to brain research in Europe. European Journal of Neurology, 2007, 14, 597-597. | 1.7 | 0 |
| 213 | IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. Experimental Brain Research, 2007, 178, 462-469. | 0.7 | 18 |
| 214 | Neutralising antibodies to interferon Î² in multiple sclerosis. Journal of Neurology, 2007, 254, 827-837. | 1.8 | 48 |
| 215 | Cognitive impairment in newly diagnosed multiple sclerosis patients: A 4-year follow-up study. Journal of the Neurological Sciences, 2006, 245, 77-85. | 0.3 | 75 |
| 216 | The relationship between MRI and PET changes and cognitive disturbances in MS. Journal of the Neurological Sciences, 2006, 245, 99-102. | 0.3 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | A prospective PET study of patients with glioblastoma multiforme. Acta Neurologica Scandinavica, 2006, 113, 412-418. | 1.0 | 2 |
| 218 | Dynamic T-lymphocyte Chemokine Receptor Expression Induced by Interferon-beta Therapy in Multiple Sclerosis. Scandinavian Journal of Immunology, 2006, 64, 155-163. | 1.3 | 26 |
| 219 | Neutralising antibodies to interferon-Î²â€“measurement, clinical relevance, and management. Journal of Neurology, 2006, 253, vi16-vi22. | 1.8 | 2 |
| 220 | CD4+ memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. Journal of Neuroimmunology, 2006, 181, 157-164. | 1.1 | 51 |
| 221 | Remyelination is extensive in a subset of multiple sclerosis patients. Brain, 2006, 129, 3165-3172. | 3.7 | 667 |
| 222 | Correlation of Global N-Acetyl Aspartate With Cognitive Impairment in Multiple Sclerosis. Archives of Neurology, 2006, 63, 533. | 4.9 | 61 |
| 223 | Neutralizing antibodies hamper IFNÂ bioactivity and treatment effect on MRI in patients with MS. Neurology, 2006, 67, 1681-1683. | 1.5 | 60 |
| 224 | The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. Multiple Sclerosis Journal, 2006, 12, 235-242. | 1.4 | 65 |
| 225 | Measuring and evaluating interferon b-induced antibodies in patients with multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 39-46. | 1.4 | 35 |
| 226 | Persistence of neutralizing antibodies after discontinuation of IFNÎ² therapy in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 247-252. | 1.4 | 51 |
| 227 | Immunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Multiple Sclerosis Journal, 2006, 12, 253-264. | 1.4 | 28 |
| 228 | The Six Spot Step Test: a new measurement for walking ability in multiple sclerosis. Multiple Sclerosis Journal, 2006, 12, 495-500. | 1.4 | 104 |
| 229 | EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. European Journal of Neurology, 2005, 12, 939-946. | 1.7 | 123 |
| 230 | Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. European Journal of Neurology, 2005, 12, 817-827. | 1.7 | 226 |
| 231 | Multiple sclerosis: pathophysiology revisited. Lancet Neurology, The, 2005, 4, 9-10. | 4.9 | 14 |
| 232 | Multi-slice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis. Magnetic Resonance in Medicine, 2005, 53, 750-759. | 1.9 | 25 |
| 233 | Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology, 2005, 65, 33-39. | 1.5 | 190 |
| 234 | Therapeutic Considerations for Disease Progression in Multiple Sclerosis. Archives of Neurology, 2005, 62, 1519-30. | 4.9 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | CD26+CD4+T cell counts and attack risk in interferon-treated multiple sclerosis. Multiple Sclerosis Journal, 2005, 11, 641-645. | 1.4 | 14 |
| 236 | Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. Neurological Research, 2005, 27, 591-597. | 0.6 | 20 |
| 237 | Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale. Multiple Sclerosis Journal, 2005, 11, 81-84. | 1.4 | 30 |
| 238 | MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). Multiple Sclerosis Journal, 2005, 11, 433-440. | 1.4 | 47 |
| 239 | Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Journal of the Neurological Sciences, 2005, 233, 61-65. | 0.3 | 41 |
| 240 | Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. Multiple Sclerosis Journal, 2004, 10, 5-8. | 1.4 | 24 |
| 241 | IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology, 2004, 63, 2028-2033. | 1.5 | 107 |
| 242 | Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens, 2004, 63, 237-247. | 1.0 | 130 |
| 243 | Early-Stage Multiple Sclerosis. Drugs, 2004, 64, 2021-2029. | 4.9 | 1 |
| 244 | Significantly increased fractions of transformed to total Î±2-macroglobulin concentrations in plasma from patients with multiple sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1690, 203-207. | 1.8 | 17 |
| 245 | Neutralising antibodies against interferon beta in multiple sclerosis. Lancet, The, 2004, 363, 168-169. | 6.3 | 3 |
| 246 | Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet, The, 2004, 364, 1149-1156. | 6.3 | 181 |
| 247 | Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology, 2004, 63, S42-9. | 1.5 | 23 |
| 248 | Association between an interleukin-13 promoter polymorphism and atopy. International Journal of Immunogenetics, 2003, 30, 355-359. | 1.2 | 73 |
| 249 | Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients. Journal of Neuroimmunology, 2003, 143, 101-106. | 1.1 | 15 |
| 250 | Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon Î²1a. Annals of Neurology, 2003, 53, 718-724. | 2.8 | 120 |
| 251 | The role of intravenous immunoglobulin in the treatment of multiple sclerosis. Journal of the Neurological Sciences, 2003, 206, 123-130. | 0.3 | 32 |
| 252 | Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet, The, 2003, 362, 1184-1191. | 6.3 | 366 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Risk Factors for Acute Respiratory Tract Infections in Young Greenlandic Children. American Journal of Epidemiology, 2003, 158, 374-384. | 1.6 | 98 |
| 254 | Antibodies to IFN-beta. Neurology, 2003, 61, S27-8. | 1.5 | 8 |
| 255 | Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). Multiple Sclerosis Journal, 2002, 8, 295-298. | 1.4 | 55 |
| 256 | Population-Based Study of Acute Respiratory Infections in Children, Greenland. Emerging Infectious Diseases, 2002, 8, 586-593. | 2.0 | 57 |
| 257 | Reporting clinical trials: full access to all the data. European Journal of Neurology, 2002, 9, 123-124. | 1.7 | 4 |
| 258 | Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. European Journal of Neurology, 2002, 9, 557-563. | 1.7 | 121 |
| 259 | A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. Genes and Immunity, 2002, 3, 279-285. | 2.2 | 73 |
| 260 | Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet, The, 2001, 357, 1576-1582. | 6.3 | 1,025 |
| 261 | Correlations of brain MRI parameters to disability in multiple sclerosis. Acta Neurologica Scandinavica, 2001, 104, 24-30. | 1.0 | 37 |
| 262 | The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. Genes and Immunity, 2001, 2, 263-268. | 2.2 | 44 |
| 263 | Linkage analysis suggests a region of importance for multiple sclerosis in 3p14â€“13. Genes and Immunity, 2001, 2, 451-454. | 2.2 | 4 |
| 264 | No linkage or association of the nitric oxide synthase genes to multiple sclerosis. Journal of Neuroimmunology, 2001, 119, 95-100. | 1.1 | 18 |
| 265 | Acute Respiratory Tract Infections and Mannose-Binding Lectin Insufficiency During Early Childhood. JAMA - Journal of the American Medical Association, 2001, 285, 1316. | 3.8 | 381 |
| 266 | Immunogenicity of interferon-? in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. Annals of Neurology, 2000, 48, 706-712. | 2.8 | 224 |
| 267 | A new millennium? Perhaps. A new European Journal of Neurology? Certainly!. European Journal of Neurology, 2000, 7, 1-1. | 1.7 | 2 |
| 268 | Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. International Journal of Radiation Oncology Biology Physics, 2000, 46, 1163-1169. | 0.4 | 231 |
| 269 | Linkage analysis of a candidate region in Scandinavian sib pairs with multiple sclerosis reveals linkage to chromosome 17q. Genes and Immunity, 2000, 1, 456-459. | 2.2 | 29 |
| 270 | Correlates of heterosexual behavior among 23-87 year olds in Denmark and Sweden, 1992-1998. Archives of Sexual Behavior, 2000, 29, 91-106. | 1.2 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | The Effect on MRI of Gammaglobulin Treatment in Relapsing Multiple Sclerosis. Multiple Sclerosis Journal, 2000, 6, S14-S17. | 1.4 | 1 |
| 272 | Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet, The, 2000, 355, 2189-2193. | 6.3 | 338 |
| 273 | Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet, The, 2000, 355, 2194-2198. | 6.3 | 295 |
| 274 | Intravenous Immunoglobulin Treatment in Neurologic Disorders. Archives of Neurology, 1999, 56, 1025. | 4.9 | 6 |
| 275 | Smoking and oral contraceptives as risk factors for cervical carcinomaIn situ. , 1999, 81, 357-365. | | 91 |
| 276 | Radiologic features compared to clinical findings in a prospective study of 153 patients with metastatic spinal cord compression treated by radiotherapy. Acta Neurochirurgica, 1997, 139, 105-111. | 0.9 | 19 |
| 277 | Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis. Multiple Sclerosis Journal, 1996, 1, 349-352. | 1.4 | 6 |
| 278 | Sumatriptan has no clinically relevant effect in the treatment of episodic tensionâ€type headache. European Journal of Neurology, 1996, 3, 23-28. | 1.7 | 63 |
| 279 | Central motor conduction as a measure of disease progression in early multiple sclerosis. European Journal of Neurology, 1995, 1, 233-241. | 1.7 | 2 |
| 280 | Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. International Journal of Radiation Oncology Biology Physics, 1995, 33, 595-598. | 0.4 | 46 |
| 281 | Cerebrospinal fluid flow and production in patients with normal pressure hydrocephalus studied by MRI. Neuroradiology, 1994, 36, 210-215. | 1.1 | 114 |
| 282 | Assessment of CSF dynamics and venous flow in the superior sagittal sinus by MRI in idiopathic intracranial hypertension: a preliminary study. Neuroradiology, 1994, 36, 350-354. | 1.1 | 52 |
| 283 | Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. European Journal of Cancer, 1994, 30, 396-398. | 1.3 | 224 |
| 284 | Tolfenamic acid versus propranolol in the prophylactic treatment of migraine. Acta Neurologica Scandinavica, 1994, 89, 446-450. | 1.0 | 10 |
| 285 | Comparison of myelography combined with postmyelographic spinal CT and MRI in suspected metastatic disease of the spinal canal. Journal of Neuro-Oncology, 1992, 13, 231-7. | 1.4 | 23 |
| 286 | Flunarizine Versus Metoprolol in Migraine Prophylaxis: A Double-Blind, Randomized Parallel Group Study of Efficacy and Tolerability. Headache, 1991, 31, 650-657. | 1.8 | 68 |
| 287 | Intracranial pressure and cerebrospinal fluid outflow conductance in healthy subjects. Journal of Neurosurgery, 1991, 74, 597-600. | 0.9 | 162 |
| 288 | Carotid artery disease and low cerebral perfusion pressure: symptomatology, operative risk and outcome. Neurological Research, 1990, 12, 35-40. | 0.6 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Metastatic spinal cord compression. Acta Neurochirurgica, 1990, 107, 37-43. | 0.9 | 347 |
| 290 | Sexual dysfunction in male and female patients with epilepsy: A study of 86 outpatients. Archives of Sexual Behavior, 1990, 19, 1-14. | 1.2 | 79 |
| 291 | Metastatic epidural spinal cord compression. Results of treatment and survival. Cancer, 1990, 65, 1502-1508. | 2.0 | 209 |
| 292 | Long-term prognosis and quality of life after reversible cerebral ischemic attacks. Acta Neurologica Scandinavica, 1989, 79, 204-213. | 1.0 | 32 |
| 293 | Prophylactic Effect of Flunarizine versus Metoprolol in Migraine. Cephalalgia, 1989, 9, 355-356. | 1.8 | 5 |
| 294 | Clinical course and prognosis of pseudotumor cerebri. A prospective study of 24 patients. Acta Neurologica Scandinavica, 1988, 77, 164-172. | 1.0 | 71 |
| 295 | Do concentrations of neurotransmitters measured in lumbar cerebrospinal fluid reflect the concentrations at brain level?. Acta Neurochirurgica, 1988, 91, 55-59. | 0.9 | 25 |
| 296 | Stroke incidence and risk factors for stroke in Copenhagen, Denmark.. Stroke, 1988, 19, 1345-1353. | 1.0 | 235 |
| 297 | Danish very-low-dose aspirin after carotid endarterectomy trial.. Stroke, 1988, 19, 1211-1215. | 1.0 | 112 |
| 298 | CSFâ€amine metabolites in depression, dementia and in controls. Acta Psychiatrica Scandinavica, 1987, 75, 619-628. | 2.2 | 34 |
| 299 | Intracerebral haemorrhage after carotid endarterectomy. European Journal of Vascular Surgery, 1987, 1, 51-60. | 0.9 | 77 |
| 300 | Cerebral blood flow in patients with normal-pressure hydrocephalus before and after shunting. Journal of Neurosurgery, 1987, 66, 379-387. | 0.9 | 92 |
| 301 | Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. Acta Neurochirurgica, 1987, 86, 93-97. | 0.9 | 31 |
| 302 | Resistance to cerebrospinal fluid outflow and intracranial pressure in patients with hydrocephales after subarachnoid haemorrhage. Acta Neurochirurgica, 1987, 88, 79-86. | 0.9 | 57 |
| 303 | Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small-cell lung cancer.. Journal of Clinical Oncology, 1986, 4, 1620-1627. | 0.8 | 27 |
| 304 | A Placebo-Controlled, Double-Blind, Cross-Over Trial of Flunarizine in Common Migraine. Cephalalgia, 1986, 6, 7-14. | 1.8 | 84 |
| 305 | Studies of vasopressin in the human cerebrospinal fluid. Acta Neurologica Scandinavica, 1986, 74, 81-102. | 1.0 | 42 |
| 306 | Motor Disturbances in Normal-Pressure Hydrocephalus. Archives of Neurology, 1986, 43, 34. | 4.9 | 86 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Endocrine Studies in Patients With Pseudotumor Cerebri. Archives of Neurology, 1986, 43, 902. | 4.9 | 54 |
| 308 | Persistent disturbances of cognitive functions in patients with pseudotumor cerebri. Acta Neurologica Scandinavica, 1986, 73, 264-268. | 1.0 | 41 |
| 309 | Severe headache as the only symptom of long-standing shunt dysfunction in hydrocephalic children with normal or slit ventricles revealed by computed tomography. Child's Nervous System, 1985, 1, 49-52. | 0.6 | 26 |
| 310 | Cerebrospinal fluid and plasma vasopressin during short-time induced intracranial hypertension. Acta Neurochirurgica, 1985, 77, 46-51. | 0.9 | 10 |
| 311 | Cerebrospinal fluid vasopressin as a marker of central nervous system metastases from small-cell bronchogenic carcinoma.. Journal of Clinical Oncology, 1985, 3, 48-53. | 0.8 | 16 |
| 312 | Visual Evoked Potentials in Pseudotumor Cerebri. Archives of Neurology, 1985, 42, 150-153. | 4.9 | 38 |
| 313 | 24-hour cerebrospinal fluid levels of vasopressin in hydrocephalic patients. Regulatory Peptides, 1985, 10, 115-126. | 1.9 | 9 |
| 314 | High cerebrospinal fluid concentration of glial fibrillary acidic protein (GFAP) in patients with normal pressure hydrocephalus. Journal of the Neurological Sciences, 1985, 70, 269-274. | 0.3 | 49 |
| 315 | Cardiac Disease in Patients with Reversible Cerebral Ischemic Events. Acta Medica Scandinavica, 1985, 217, 417-421. | 0.0 | 2 |
| 316 | Ophthalmologic prognosis in Benign Intracranial Hypertension. Acta Ophthalmologica, 1985, 63, 62-64. | 0.6 | 9 |
| 317 | Bone lesions in early syphilis detected by bone scintigraphy.. Sexually Transmitted Infections, 1984, 60, 265-268. | 0.8 | 11 |
| 318 | Impermeability of the bloodâ€cerebrospinal fluid barrier to 1â€deaminoâ€8â€Dâ€arginineâ€vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus. European Journal of Clinical Investigation, 1984, 14, 435-439. | 1.7 | 39 |
| 319 | Cerebrospinal fluid vasopressin and increased intracranial pressure. Annals of Neurology, 1984, 15, 435-440. | 2.8 | 46 |
| 320 | Effects of long-term carbamazepine treatment on water metabolism and plasma vasopressin concentration. European Journal of Clinical Pharmacology, 1984, 26, 719-722. | 0.8 | 23 |
| 321 | Plasma Vasopressin, Cortisol, and Growth Hormone Concentrations in Relation to Surgery in the Suprasellar Region. Acta Medica Scandinavica, 1984, 216, 31-39. | 0.0 | 2 |
| 322 | Prevalence of Mitral Valve Prolapse in Younger Patients with Cerebral Ischaemic Attacks. Acta Medica Scandinavica, 1984, 216, 385-391. | 0.0 | 18 |
| 323 | Low cerebrospinal fluid concentration of brain-specific protein D2 in patients with normal pressure hydrocephalus. Journal of the Neurological Sciences, 1983, 62, 59-65. | 0.3 | 29 |
| 324 | Prognostic Value of in vitro Measurements of Platelet Aggregability and Fibrinolytic Activity in Patients with Reversible Cerebral Ischemic Attacks. European Neurology, 1983, 22, 437-441. | 0.6 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | A Case of Malignant Lymphoma and Myasthenia Gravis. Scandinavian Journal of Haematology, 1983, 31, 155-160. | 0.0 | 11 |
| 326 | Vasopressin release during electroconvulsive therapy. Psychoneuroendocrinology, 1982, 7, 303-308. | 1.3 | 15 |
| 327 | Vasopressin in the cerebrospinal fluid of patients with normal pressure hydrocephalus and benign intracranial hypertension. European Journal of Endocrinology, 1982, 100, 211-215. | 1.9 | 31 |
| 328 | Prevalence of stroke in a district of Copenhagen. Acta Neurologica Scandinavica, 1982, 66, 68-81. | 1.0 | 61 |
| 329 | Electroconvulsive therapy: A comparison of seizure duration as monitored with electroencephalograph and electromyograph. Acta Psychiatrica Scandinavica, 1981, 64, 193-198. | 2.2 | 12 |
| 330 | Essential tremor treated with propranolol: Lack of correlation between clinical effect and plasma propranolol levels. Annals of Neurology, 1981, 9, 53-57. | 2.8 | 25 |
| 331 | Long-term prognosis after transient ischemic attacks. Acta Neurologica Scandinavica, 1981, 63, 156-168. | 1.0 | 42 |
| 332 | The incidence and clinical presentation of neurosyphilis in Greater Copenhagen 1974 through 1978. Acta Neurologica Scandinavica, 1981, 63, 237-246. | 1.0 | 15 |
| 333 | Elektromyografisk monitorering ved narko-curare-elektrostimulation. Nordic Journal of Psychiatry, 1979, 33, 9-14. | 0.2 | 1 |
| 334 | Giantâ€cell Arteritis, Temporal Arteritis and Polymyalgia Rheumatica. Acta Medica Scandinavica, 1977, 201, 207-213. | 0.0 | 108 |
| 335 | Treatment of Hookworm Anemia. Scandinavian Journal of Infectious Diseases, 1971, 3, 65-69. | 1.5 | 3 |
| 336 | Neutralizing antibodies directed against biologic agents to treat multiple sclerosis. , 0, , 287-299. | | 0 |
| 337 | Intravenous immunoglobulin to treat multiple sclerosis. , 0, , 444-453. | | 0 |